A Multi-Center, Open-Label, Single-Arm Study to Investigate the Early Effectiveness of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Using a Mobile Self-Monitoring Application.
Pharmaceuticals (Basel, Switzerland) August 30, 2024 Junhyung Kim, Seung-Hoon Lee, Cheolmin Shin et al. 8 citations
In adults with treatment-resistant depression, esketamine nasal spray combined with daily self-monitoring through a mobile app produced significant reductions in depressive and anxiety symptoms as early as one day after the first dose. The open-label study enrolled 18-65 year olds who had failed at least two prior antidepressant therapies. Participants used the EsCARe app to track mood, sleep, and somatic symptoms alongside standard clinical assessments. By week 2, scores on the Patient Health Questionnaire-9 and Generalized Anxiety Disorder Scale had notably decreased; the Hamilton Depression Rating Scale showed improvement by week 4. The mobile app reliably and validly tracked depressive symptoms, offering patients and clinicians immediate feedback on treatment effectiveness.